- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
Folate hydrolase 1 (FOLH1), also known as Prostate-specific membrane antigen (PSMA), Glutamate carboxypeptidase II (GCPII), and NAALADase, is a membrane-associated metallopeptidase involved in folate metabolism and glutamatergic signaling pathways. FOLH1 Antibody / Prostate Cancer and PSMA Marker is useful for studying prostate tumor biology, membrane-associated enzymatic signaling, and epithelial differentiation pathways associated with prostate cancer progression. FOLH1 antibody, also referred to as PSMA antibody and Prostate-specific membrane antigen antibody in the literature, recognizes a type II transmembrane glycoprotein highly expressed in prostate epithelium and prostate carcinoma cells.
FOLH1 is predominantly localized to the plasma membrane where it functions as a folate hydrolase and neuropeptidase involved in cleavage of folate polyglutamates and N-acetylaspartylglutamate substrates. In normal tissues, expression is observed in prostate epithelium, kidney proximal tubules, small intestine, salivary gland, and selected neural tissues. The protein participates in nutrient metabolism and glutamatergic signaling pathways while also serving as a highly recognized prostate-associated membrane marker in cancer biology research.
Because FOLH1 expression is strongly enriched in prostate carcinoma, this target has become highly important in studies focused on prostate cancer progression, metastatic disease, tumor imaging, and targeted therapeutic development. Increased PSMA expression has been associated with aggressive tumor behavior, androgen-independent progression, and tumor-associated neovasculature in multiple malignancies. FOLH1 is widely used as a marker of prostate epithelial differentiation and remains one of the most clinically relevant membrane proteins in prostate cancer research.
In addition to prostate biology, FOLH1 contributes to glutamate signaling regulation within the nervous system and participates in folate metabolism pathways associated with cellular growth and metabolic homeostasis. Expression patterns have also been investigated in renal tissue, gastrointestinal epithelium, and tumor-associated endothelial compartments. Immunohistochemistry studies commonly demonstrate strong membranous and cytoplasmic staining patterns in prostate carcinoma tissues, while western blot analysis identifies the expected high molecular weight glycoprotein species associated with FOLH1 expression.
A mouse monoclonal clone FOLH1/2363 antibody can be used for immunohistochemistry, western blot, and protein microarray specificity validation studies examining prostate cancer-associated signaling and membrane protein expression pathways. Because FOLH1 functions as both a membrane-associated enzyme and prostate cancer marker, this target remains highly relevant for studies focused on prostate tumor biology, epithelial differentiation, folate metabolism, and targeted cancer research applications.
Researchers studying prostate tumor biology, PSMA-associated signaling, and epithelial differentiation pathways may also be interested in our broader Cancer Antibodies collection featuring markers involved in tumor progression, membrane signaling, and cancer-associated metabolic regulation.
Optimal dilution of the FOLH1 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
A portion of amino acids 232-433 from the human protein was used as the immunogen for this FOLH1 antibody.
Store the FOLH1 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
PSMA antibody, FOLH1 prostate cancer antibody, Prostate-specific membrane antigen antibody, Glutamate carboxypeptidase II antibody, GCPII antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.